0001171843-24-001275.txt : 20240311
0001171843-24-001275.hdr.sgml : 20240311
20240311101203
ACCESSION NUMBER: 0001171843-24-001275
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240308
FILED AS OF DATE: 20240311
DATE AS OF CHANGE: 20240311
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Boylan James P
CENTRAL INDEX KEY: 0001953094
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39696
FILM NUMBER: 24736883
MAIL ADDRESS:
STREET 1: C/O ENAVATE SCIENCES
STREET 2: 2884 SAND HILL RD., STE 100
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Compass Therapeutics, Inc.
CENTRAL INDEX KEY: 0001738021
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 80 GUEST STREET
CITY: BOSTON
STATE: MA
ZIP: 02135
BUSINESS PHONE: 617-500-8099
MAIL ADDRESS:
STREET 1: 80 GUEST STREET
CITY: BOSTON
STATE: MA
ZIP: 02135
FORMER COMPANY:
FORMER CONFORMED NAME: Olivia Ventures, Inc.
DATE OF NAME CHANGE: 20180419
4
1
ownership.xml
X0508
4
2024-03-08
0
0001738021
Compass Therapeutics, Inc.
CMPX
0001953094
Boylan James P
C/O COMPASS THERAPEUTICS, INC.
80 GUEST STREET, SUITE 601
BOSTON
MA
02135
1
0
0
0
0
Stock Option (Right to Buy)
1.96
2024-03-08
4
A
0
40000
0
A
2034-03-07
Common Stock
40000
40000
D
The options vest over 48 substantially equal monthly installments starting April 8, 2024.
The Reporting Person is a member of Enavate Sciences, LP ("Enavate"). Pursuant to an agreement with Enavate, the Reporting Person has agreed to receive and hold for the benefit of Enavate any securities issued under any stock options or other awards granted to him for his services as a director on the Issuer's board of directors. As such, the Reporting Person disclaims beneficial ownership of, and all right, title and interest in, the reported securities.
/s/ Neil Lerner, as attorney-in-fact
2024-03-11